Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06159283

Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell Impairment

Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell Impairment: a Multicenter Randomized Controlled Trial

Sponsor: Jaehoon Ko

Conditions COVID-19

Interventions Immunoglobulins

Updated 6 times since 2024 Last updated: May 13, 2024 Started: Mar 18, 2024 Primary completion: Jun 30, 2025 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on COVID-19, this trial is actively recruiting participants. The trial is conducted by Jaehoon Ko and has accumulated 6 data snapshots since 2024. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE2
Sep 2024 — Sep 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Apr 2024 — Jun 2024 [monthly]

Not Yet Recruiting PHASE2

▶ Show 1 earlier version

Jan 2024 — Apr 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jaehoon Ko

Data source: Samsung Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea